Skip to main content
Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc. — Investor Relations & Filings

Ticker · EWTX ISIN · US28036F1057 US Manufacturing
Open in API
Filings indexed 372 across all filing types
Latest filing 2024-08-14 Director's Dealing
Country US United States of America
Listing US EWTX

About Edgewise Therapeutics, Inc.

https://edgewisetx.com/

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for severe and rare muscle disorders. The company leverages its expertise in muscle science to create precision medicines for conditions including muscular dystrophies and serious cardiac diseases. Its primary goal is to develop treatments that address the underlying causes of these debilitating conditions to improve the lives of patients and their families.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-08-14 English
PRIMARY DOCUMENT
Director's Dealing
2024-08-14 English
PRIMARY DOCUMENT
Director's Dealing
2024-08-14 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the adoption of a new equity incentive plan by the company's board of directors, including the reservation of shares and the terms of the plan. This relates to changes in the company's management compensation and equity plans but does not constitute a full annual or quarterly report, earnings release, or other financial statement. The key section is Item 5.02, which covers departure or election of directors or officers and related compensatory arrangements. This aligns with the category for Board/Management Information (MANG). The document is not a proxy statement, merger filing, or other category. Therefore, the correct classification is MANG with high confidence.
2024-08-12 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-08 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2024, by Edgewise Therapeutics, Inc. It announces the issuance of a press release regarding financial results for the second quarter ended June 30, 2024. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference, and that the information is "furnished" and not "filed" for certain regulatory purposes. The document itself does not contain the financial results or detailed financial statements but rather announces their release. The length of the document is 4161 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain the full financial data or detailed analysis required for an Earnings Release (ER) or Interim Report (IR).
2024-08-08 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.